Technology
Health
Pharmaceutical
Apellis Pharmaceuticals
$29.169876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$29.16
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$1.97 (7.25%) Today
$0.00 (0.00%) As of 4:19 PM EDT after-hours
Why Robinhood?
You can buy or sell APLS and other stocks, options, ETFs, and crypto commission-free!
About APLS
Apellis Pharmaceuticals, Inc. Common Stock, also called Apellis Pharmaceuticals, is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. Read More It develops complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Crestwood, KY.
Employees
87
Headquarters
Crestwood, Kentucky
Founded
2009
Market Cap
1.72B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
382.01K
High Today
$29.49
Low Today
$27.08
Open Price
$27.39
Volume
364.41K
52 Week High
$29.49
52 Week Low
$11.45
Collections
Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
2017 IPO
US
North America
Price Paid on Robinhood
60% Higher
Right Now
52 Week Low
$11.45
Average Price Paid
$18.25
52 Week High
$26.13
Analyst Ratings
83%
of 6 ratings
Buy
83%
Hold
17%
Sell
0%
APLS Earnings
-$0.87
-$0.72
-$0.58
-$0.43
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Jul 30, Pre-Market